Eugene Kim1, Jana Kim1, Gunhild Mari Maelandsmo2, Berit Johansen3, Siver Andreas Moestue1. 1. Department of Circulation and Medical Imaging, NTNU, Norwegian University of Science and Technology, Trondheim, Norway. 2. Department of Tumor Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. 3. Department of Biology, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.
Abstract
PURPOSE: To compare the effects of two anti-angiogenic drugs, bevacizumab and a cytosolic phospholipase A2-α inhibitor (AVX235), on the relationship between vascular structure and dynamic contrast enhanced (DCE)-MRI measurements in a patient-derived breast cancer xenograft model. METHODS: Mice bearing MAS98.12 tumors were randomized into three groups: bevacizumab-treated (n = 9), AVX235-treated (n = 9), and control (n = 8). DCE-MRI was performed pre- and post-treatment. Median initial area under the concentration-time curve (IAUC60 ) and volume transfer constant (Ktrans ) were computed for each tumor. Tumors were excised for ex vivo micro-CT (computed tomography) angiography, from which the vascular surface area (VSA) and fractional blood volume (FBV) were computed. Spearman correlation coefficients (ρ) were computed to evaluate the associations between the DCE-MRI and micro-CT parameters. RESULTS: With the groups pooled, IAUC60 and Ktrans correlated significantly with VSA (ρ = 0.475 and 0.527; P = 0.019 and 0.008). There were no significant correlations within the control group. There were various significant correlations within the treatment groups, but the correlations in the bevacizumab group were of opposite sign, for example, Ktrans versus FBV: AVX235, ρ = 0.800 (P = 0.014); bevacizumab, ρ = -0.786 (P = 0.023). CONCLUSION: DCE-MRI measurements can highly depend on vascular structure. The relationship between vascular structure and function changed markedly after anti-angiogenic treatment. Magn Reson Med 78:1513-1522, 2017.
PURPOSE: To compare the effects of two anti-angiogenic drugs, bevacizumab and a cytosolic phospholipase A2-α inhibitor (AVX235), on the relationship between vascular structure and dynamic contrast enhanced (DCE)-MRI measurements in a patient-derived breast cancer xenograft model. METHODS:Mice bearing MAS98.12 tumors were randomized into three groups: bevacizumab-treated (n = 9), AVX235-treated (n = 9), and control (n = 8). DCE-MRI was performed pre- and post-treatment. Median initial area under the concentration-time curve (IAUC60 ) and volume transfer constant (Ktrans ) were computed for each tumor. Tumors were excised for ex vivo micro-CT (computed tomography) angiography, from which the vascular surface area (VSA) and fractional blood volume (FBV) were computed. Spearman correlation coefficients (ρ) were computed to evaluate the associations between the DCE-MRI and micro-CT parameters. RESULTS: With the groups pooled, IAUC60 and Ktrans correlated significantly with VSA (ρ = 0.475 and 0.527; P = 0.019 and 0.008). There were no significant correlations within the control group. There were various significant correlations within the treatment groups, but the correlations in the bevacizumab group were of opposite sign, for example, Ktrans versus FBV: AVX235, ρ = 0.800 (P = 0.014); bevacizumab, ρ = -0.786 (P = 0.023). CONCLUSION:DCE-MRI measurements can highly depend on vascular structure. The relationship between vascular structure and function changed markedly after anti-angiogenic treatment. Magn Reson Med 78:1513-1522, 2017.
Authors: Einar Sulheim; Jana Kim; Annemieke van Wamel; Eugene Kim; Sofie Snipstad; Igor Vidic; Ingeborg Hovde Grimstad; Marius Widerøe; Sverre H Torp; Steinar Lundgren; David J Waxman; Catharina de Lange Davies Journal: J Control Release Date: 2018-04-21 Impact factor: 9.776
Authors: Michael A Pinkert; Lonie R Salkowski; Patricia J Keely; Timothy J Hall; Walter F Block; Kevin W Eliceiri Journal: J Med Imaging (Bellingham) Date: 2018-01-22
Authors: John M Hudson; Colleen Bailey; Mostafa Atri; Greg Stanisz; Laurent Milot; Ross Williams; Alex Kiss; Peter N Burns; Georg A Bjarnason Journal: Eur Radiol Date: 2018-01-30 Impact factor: 5.315
Authors: Anna Woloszyk; Petra Wolint; Anton S Becker; Andreas Boss; Weston Fath; Yinghua Tian; Simon P Hoerstrup; Johanna Buschmann; Maximilian Y Emmert Journal: Sci Rep Date: 2019-12-19 Impact factor: 4.379
Authors: Pavitra Kannan; Warren W Kretzschmar; Helen Winter; Daniel Warren; Russell Bates; Philip D Allen; Nigar Syed; Benjamin Irving; Bartlomiej W Papiez; Jakob Kaeppler; Bosjtan Markelc; Paul Kinchesh; Stuart Gilchrist; Sean Smart; Julia A Schnabel; Tim Maughan; Adrian L Harris; Ruth J Muschel; Mike Partridge; Ricky A Sharma; Veerle Kersemans Journal: Clin Cancer Res Date: 2018-06-29 Impact factor: 12.531